Marinus Pharmaceuticals — Patent Portfolio
1 drug with active patents · 11 active patents · 0 expired · 0 biologics with BPCIA exclusivity
Verdict Marinus Pharmaceuticals' patent portfolio is moderately strong, with a significant cliff year in 2026 and no revenue at risk in the next 5 years.
Portfolio overview Marinus Pharmaceuticals has a total of 1 drug with patents, out of 1 total drugs in their portfolio. Their patent estate consists of 11 active US patents with an average vulnerability score of 73, indicating a moderate level of risk. Notably, none of their patents are considered ironclad, while 6 are vulnerable.
Cliff calendar In 2026, 1 drug will lose exclusivity, including Ztalmy. This marks a significant cliff year for the company, with a notable loss of revenue protection.
Most exposed drugs The top drug facing near-term loss of exclusivity is Ztalmy, with an earliest active patent expiry date of 2026-11-28, an average vulnerability score of 73, and no annual revenue data available. This drug has 11 patents in its estate.
Biologic exclusivity Marinus Pharmaceuticals does not have any biologics in their portfolio, meaning they do not have any BPCIA 12-year reference product exclusivity to consider.
Strategic implications With no revenue at risk in the next 5 years, Marinus Pharmaceuticals has a relatively stable patent estate. However, the company should consider lifecycle moves to maintain revenue growth, such as subQ switches, label extensions, or combination filings, to mitigate the impact of the 2026 cliff year.
Loss of exclusivity calendar · next 12 years
Drugs facing US patent or BPCIA biologic exclusivity loss per year. Click any year to see the broader cliff calendar for the industry.
Patent estate by drug
Ztalmy (GANAXOLONE)
Cliff 2026 · 0y-
US8618087
Vuln 88
2026-11-28
This patent protects methods for making and using solid formulations of ganaxolone, specifically particles with a diameter of about 50 nm to about 500 nm.
-
US9056116
Vuln 88
2026-11-28
This patent protects methods for making and using liquid formulations of ganaxolone, specifically those with stable particles of a certain size.
-
US12144801
Vuln 75
2037-08-10
This patent protects methods and compositions for treating epileptic disorders using allosteric modulators and/or gaboxadol.
Patent classification breakdown · active patents
By US patent type. Method-of-use patents are most vulnerable to design-around; composition-of-matter patents are the strongest protection.
- Method of Use 6 patents
- Formulation 5 patents
Sources
- FDA Orange Book — small-molecule patents listed against approved NDAs.
- FDA Purple Book — biologic BPCIA 12-year reference product exclusivity.
- USPTO Patent Public Search — title, abstract, claim text grounding.
- AI summaries generated by Drug Landscape, grounded in source claim text.
Patent term extensions (PTR, SPC, pediatric exclusivity) may shift effective expiry. Not legal advice.
Track Marinus Pharmaceuticals's patent estate
Daily alerts when vulnerability scores shift, patents expire, or IPRs are filed. Free tier: 3 watches. Pro tier (£199/mo): 50 watches + daily AI Pharma IP Brief.
↓ CSV export